Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel Topical Psoriasis Treatment Targets Nerve Pathways

Key clinical point: A significant number of patients receiving SNA-120 reached PASI-75 after 12 weeks of treatment.

Major finding: After 12 weeks of treatment, 27% of patients achieved PASI-75, compared with 13% of those on placebo.

Study details: Randomized, double-blind, vehicle-controlled phase 2b study of 208 adults with mild to moderate psoriasis receiving topical SNA-120 at one of two concentrations, or the vehicle ointment alone.

Disclosures: The presenter is employed by Sienna Biopharmaceuticals, which sponsored the study and is developing SNA-120.